Malignant neoplasm of fundus uteri
ICD-10 C54.3 is a billable code used to indicate a diagnosis of malignant neoplasm of fundus uteri.
C54.3 refers to a malignant neoplasm located at the fundus of the uterus, which is the uppermost part of the uterus. This type of cancer is classified under gynecologic malignancies and can arise from the endometrial lining or the myometrium. The fundus is a critical area as it is often involved in the spread of uterine cancers. Symptoms may include abnormal vaginal bleeding, pelvic pain, and changes in menstrual patterns. Diagnosis typically involves imaging studies, such as ultrasound or MRI, and histopathological examination following biopsy. Staging of the cancer is crucial for determining the treatment approach and prognosis, with the FIGO staging system commonly used. CA-125, a tumor marker, may be elevated in patients with malignant neoplasms of the uterus, although it is not specific to uterine cancer. Treatment options may include surgical resection, radiation therapy, and chemotherapy, depending on the stage and grade of the tumor. Accurate coding is essential for appropriate management and reimbursement.
Detailed pathology reports, imaging studies, and surgical notes are essential.
Patients presenting with abnormal bleeding, pelvic masses, or postmenopausal bleeding.
Ensure accurate staging and documentation of tumor characteristics to support coding.
Imaging reports must clearly indicate findings related to the fundus and any abnormalities.
Imaging for suspected uterine masses or staging of known malignancies.
Radiologists should provide clear descriptions of findings to assist in accurate coding.
Performed for malignant neoplasm of the fundus uteri.
Operative report detailing the procedure and findings.
Gynecologic oncologists should ensure comprehensive documentation of tumor characteristics.
CA-125 is a tumor marker that may be elevated in patients with malignant neoplasms of the uterus, including C54.3. It is used for diagnosis and monitoring treatment response, although it is not specific to uterine cancer.
